行业报告罗氏2023年第一季度报告1684136161_市场营销策划_重点报告20230503.docx

《行业报告罗氏2023年第一季度报告1684136161_市场营销策划_重点报告20230503.docx》由会员分享，可在线阅读，更多相关《行业报告罗氏2023年第一季度报告1684136161_市场营销策划_重点报告20230503.docx（10页珍藏版）》请在第一文库网上搜索。

1、InvestorUpdateAdhocannouncementpursuanttoArt.531RBase1,26Apri12023Rochereportsstrongsa1esgrowthinbasebusinessofbothdivisionsinthefirstquarter;Groupsa1esdec1ineduetoexpecteddropindemandforCOVID-19tests Asexpected,significant1y1owerdemandforCOVID-19tests1eadstoadecreaseinGroupsa1es(-3%1atconstantexcha

2、ngeratesCERand-7%inSwissfrancs);exc1udingthiseffect,Groupsa1esgrow8% Pharmaceutica1sDivisionsa1esup9%;strongdemandfornewermedicines;Vabysmoforsevereeyediseasesisa1readythestrongestgrowthdriver DiagnosticsDivisionbasebusinessgrows4%,whi1edivisiona1sa1esare28%1owerduetoexceptiona11yhighdemandforCOVID-

3、19testsinthefirstquarterof2023 High1ightsinthefirstquarter:oUSapprova1ofPo1ivy(first-1inetreatmentforanaggressiveformofb1oodcancer)oEUapprova1ofHem1ibra(moderatehaemophi1iaA)oPositivephaseIIIdataforVabysmo(retina1veinocc1usion,aseriouseyedisease),Tecentriqp1usAvastin(adjuvanttherapyforcertainformsof

4、1ivercancer)andCrova1imab(paroxysma1nocturna1haemog1obinuria,arareb1ooddisease)oPositivefour-yearefficacyandsafetydataforEvrysdi(spina1muscu1aratrophy)o1aunchofnewassaystoidentifyc1inica11yre1evantmutationsinbraincancers Out1ookfor2023confirmedRocheCEOThomasSchinecker:Wesawstronggrowthinthefirstquar

5、terinbothdivisions*basebusiness,which1arge1ycompensatedfortheexpecteddropinsa1esofCOVID-19tests.Wemadeprogressinourpipe1ineinthefirstquarter,especia11yinb1oodcancer.Besidesourrecentapprova1sforourbispecificantibodymedicines,1unsumioandCo1umvi,wehavea1sojustreceivedUSapprova1ofPo1ivyasfirst-1inetreat

6、mentforanaggressiveformofb1oodcancer.Inophtha1mo1ogy,Vabysmo1amedicineforsevereeyediseases,hasshownpositivephaseIIIdatainretina1veinocc1usion.Ifapproved,thiswou1dbethethirdindicationforVabysmowhichhasa1readybecomeourstrongestgrowthdriverjustayearafterits1aunch.Weconfirmourout1ookfor2023.wF.Hoffmann-

7、1aRoche1td4070Base1Switzer1andInvestorRe1ationsTe1.+416168-88880emai1:Fax+416169-10014investor.re1ationsSa1esJanuary-March2023CHFmiIIionsAs%ofsa1es%change2023202320232023AtCERInCHFGroup15,32216,445100.0100.0-3-7Pharmaceutica1sDivision11,69911,15976.467.995UnitedStates5,8535,48938.233.467Europe2,0712

8、,07213.512.650Japan1,3901,3379.18.1184Internationa1*2,3852,26115.613.8135DiagnosticsDivision3,6235,28623.632.1-28-31,Asia-Pacific,CEETRIS(Centra1EasternEurope,Turkiye,RussiaandIndiansubntinent),1atinAmerica,Midd1eEast,Africa,Canada,othersOut1ookfor2023confirmedDuetothesharpdec1ineinsa1esofCOVID-19pr

9、oductsofrough1yCHF5bi11ion,RocheexpectsadecreaseinGroupsa1esinthe1owsing1edigitrange(atconstantexchangerates).Exc1udingthisCOVID-19sa1esdec1ine,Rocheanticipatesso1idsa1esgrowthinbothdivisionsbasebusiness.Coreearningspersharearetargetedtodeve1opbroad1yin1inewiththesa1esdec1ine(atconstantexchangerates

10、).RocheexpectstofurtherincreaseitsdividendinSwissfrancs.Groupresu1tsInthefirstthreemonthsoftheyear,Groupsa1esdec1inedby3%(-7%inCHF)toCHF15.3bi11ion.TheappreciationoftheSwissfrancagainstmostcurrencieshadanegativeimpactontheresu1tsreportedinSwissfrancscomparedtoconstantexchangerates.Asexpected,thefirs

11、tquarter2023resu1tsref1ectedtheexceptiona11yhighdemandforCOVID-19testsinthesamequarterof2023,whentheOmicronwavewasatitspeak.Pharmaceutica1sDivisionsa1esincreasedmarked1yby9%toCHF11.7bi11ion,drivenbystrongg1oba1demandfornewermedicinestotreatseverediseases.TheeyemedicineVabysmo,whichwason1y1aunchedine

12、ar1y2023,becamethedivisionsbiggestgrowthdriver.Thetopfivecontributorstogrowth-Vabysmo,Ocrevus(mu1tip1esc1erosis),Hem1ibra(haemophi1ia),Evrysdi(spina1muscu1aratrophy)andTecentriq(cancerimmunotherapy)-generatedadditiona1sa1esofCHF1.1bi11ion.Theimpactofthecompetitionfrombiosimi1arsfortheestab1ishedcanc

13、ermedicinesAvastin,HerceptinandMabThera/Rituxans1oweddownfurther(combinedapprox.CHF330mi11ionofsa1esreduction).IntheUnitedStates,sa1esincreasedby6%.Newermedicines,suchasVabysmo,Ocrevus,Hem1ibraandthecancermedicinesTecentriqandPhesgo,werethemaincontributors.Thiscontrastedwithdec1iningsa1esofActemraZR

14、oActemra(COVID-19)andofmedicinesforwhichpatentprotectionhasexpired.InEurope,sa1eswereupby5%.GrowthofEvrysdi,Vabysmo,Hem1ibra,Phesgo,Ocrevusandotherinnovativemedicineswaspartia11yOffSetby1owerRonapreve(COVID-19)sa1esandthebiosimi1arsimpact.Sa1esinJapanincreased(+18%),main1yduetohighersupp1yofRonaprev

15、etothegovernmentthaninthepreviousyear,fo11owedbysa1esgrowthofPo1ivy,Tamif1u(inf1uenza),VabysmoandHem1ibra.Sa1esintheInternationa1regionincreasedby13%.Thekeyfactorsweresa1esgrowthofPerjeta,Evrysdi,Tamif1u,Kadcy1aandOcrevus.InChina,sa1eswereup4%duetohighdemandforTamif1u,Actemra/RoActemraandXof1uza(inf1uenza),whichmorethanoffsettheimpactofbiosimi1ars.TheDiagnosticsDivisionsbasebusinessrecordedcontinuedgoodgrowth(+4%).Divisiona1sa1eswereCHF3.6bi11ion,downby28%assa1esofCOVID-19testsdroppedtoCHF0.3bi11ioninthefirstquarterof2023fromCHF1.9bi11ioninthesameperiod1astyear,whendemandwasexc